Ceapro Inc. announced the expansion of its collaboration with the Angiogenesis Foundation to conduct research on characterizing healing dynamics and molecular profiling of tissue regeneration stimulated by oat-derived bioactives. This next research phase is an extension of previous studies demonstrating that Ceapro's products have biological activity. Work presented at the Annual Meeting of the Wound Healing Society (WHS) in April 2023 showed that oat-based beta glucan (BG) and avenanthramides (AV) reduce scar formation, inhibit inflammation, recruit stem cells and stimulate angiogenesis in vivo in a statistically significant manner compared to control.

The goals of the new study will be to investigate: the impact of AV and BG on the speed of wound healing at different time points; the unique profile of AV and BG on skin healing dynamics; the molecular profile of regenerative tissue repair by single cell RNA analysis; and differential effects of AV and BG on gene expression of the skin during tissue repair.